Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMD4 siRNA
- Development stage
- Preclinical
- Lead developer
- Dharmacon
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
PSMD4 siRNA is a research-grade short interfering RNA (siRNA) designed to silence the expression of the PSMD4 gene (also known as Rpn10). PSMD4 encodes a ubiquitin receptor subunit of the 19S regulatory lid of the 26S proteasome, which is responsible for recognizing and chaperoning ubiquitinated proteins for degradation. In preclinical models of multiple myeloma, PSMD4 siRNA has been shown to induce apoptosis and reduce cell viability, even in cells resistant to proteasome inhibitors like bortezomib. It is primarily used as a genetic tool to validate PSMD4 as a therapeutic target in oncology research, particularly in multiple myeloma and epithelial ovarian cancer.
- Other names
- Rpn10 siRNARpn-10 siRNARpn 10 siRNAPSMD4-siRNAPSMD-4-siRNAPSMD 4-siRNA
02
Targets
PSMD4 (Proteasome 26S subunit non-ATPase 4)
Beyond the preview
Go deeper on PSMD4 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMD4 siRNA.